Despite the largest U.S. pharmacy benefit manager (PBM) knocking Zepbound off its formulary this summer, sales of Lilly’s dual-action obesity med continue to impress, thanks in no small part to the ...
Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks Consensus Estimate of $6.02 per share. In the year-ago quarter, Lilly recorded ...
Revenue climbs more than 50% to beat expectations by a wide margin as demand for GLP-1 drugs are still booming Eli Lilly's stock rallies, as Zepbound sales nearly tripled, leading to record revenue ...
Eli Lilly LLY is a dominant player in the cardiometabolic space, all thanks to the encouraging uptake for its blockbuster GLP-1 drugs — Mounjaro (for type II diabetes [T2D]) and Zepbound (for obesity) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback